Evotec 

€6
256
+€0.07+1.18% Friday 15:02

统计数据

当日最高
6
当日最低
6
52周最高
-
52周最低
-
成交量
950
平均成交量
-
市值
-
市盈率
-
股息收益率
-
股息
-

即将到来

收益

6Nov预期
Q1 2024
Q2 2024
下一个
-0.53
-0.36
-0.2
-0.04
预期每股收益
-0.0433459653722656
实际每股收益
N/A

人们还关注

此列表基于关注1EVT.MI的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
首席执行官
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
员工
4715
国家
DE
ISIN
DE0005664809

上市公司